{
    "id": 18571,
    "cites": 34,
    "cited_by": 1,
    "reference": [
        "Acemoglu, D., and Linn, J. Market size in innovation: theory and evidence from the pharmaceutical industry. The Quarterly Journal of Economics 119, 3 (2004), 1049\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1090.",
        "Baumgardner, J. R. The interaction between forms of insurance contract and types of technical change in medical care. The RAND Journal of Economics 22 (1991), 36\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c53.",
        "Bruen, B. K., and Ghosh, A. Medicaid prescription drug spending and use. Henry J. Kaiser Family Foundation, 2004.",
        "Card, D., Dobkin, C., and Maestas, N. The impact of nearly universal insurance coverage on health care utilization and health: evidence from medicare. American Economic Review 98, 5 (2008), 2242\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2258.",
        "Carroll, N. V. Estimating the impact of medicare part d on the profitability of independent community pharmacies. J Manag Care Pharm 14, 8 (2008), 768\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c79.",
        "Cawley, J., Moriya, A. S., and Simon, K. I. The impact of the macroeconomy on health insurance coverage: Evidence from the great recession. NBER Working Paper (2011).",
        "CBO. The rebate medicaid receives on brand-name prescription drugs. retrieved August 26, 2012, from http://www.cbo.gov/sites/default/files/cbofiles/ftpdocs/ 64xx/doc6493/06\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c21\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009cmedicaidrebate.pdf.",
        "Chernew, M. E., and Newhouse, J. P. Health care spending growth. Handbook of Health Economics 2 (2012), 1\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c43.",
        "Clemens, J. The effect of us health insurance expansions on medical innovation. SIEPR Discussion Paper No. 11-016 (2012).",
        "Cochrane, J. H. Asset Pricing. Princeton University Press, 2001.",
        "Cutler, D. M., and Gruber, J. Does public insurance crowd out private insurance? The Quarterly Journal of Economics 111, 2 (1996), 391\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c430.",
        "DiMasi, J. A., et al. Risks in new drug development: approval success rates for investigational drugs. Clinical Pharmacology and Therapeutics 69, 5 (2001), 297\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c307.",
        "Duggan, M., and Morton, F. S. The effect of medicare part d on pharmaceutical prices and utilization. The American Economic Review 100, 1 (2010), 590\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c607.",
        "Engelhardt, G. V., and Grubera, J. Medicare part d and the financial protection of the elderly. American Economic Journal: Economic Policy 3, 4 (2011), 77\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c102.",
        "Finkelstein, A. Static and dynamic effects of health policy: Evidence from the vaccine industry. The Quarterly Journal of Economics 119, 2 (2004), 527\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c564.",
        "Ginsburg, P. B. Wide variation in hospital and physician payment rates evidence of provider market power. Center for Studying Health System Change Brief No 16 (2010).",
        "Ketcham, J., and Simon, K. Medicare part d\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s effects on elderly patients\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 drug costs and utilization. The American journal of managed care 14, 11 Suppl (2008), SP14.",
        "Koijen, R. S., Philipson, T. J., and Uhlig, H. Financial health economics. Working Paper, The University of Chicago (2012).",
        "Kolstad, J. T., and Kowalski, A. E. Mandate-based health reform and the labor market: Evidence from the massachusetts reform. NBER Working Paper (2012).",
        "Lichtenberg, F. R., and Sun, S. X. The impact of medicare part d on prescription drug use by the elderly. Health Affairs 26, 6 (2007), 1735\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1744.",
        "Malani, A., and Philipson, T. J. Can medical progress be sustained? implications of the link between development and output markets. NBER Working Paper (2011).",
        "Manning, W. G., Newhouse, J. P., Duan, N., Keeler, E. B., and Leibowitz, A. Health insurance and the demand for medical care: evidence from a randomized experiment. The American Economic Review (1987), 251\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c277.",
        "Neuman, P., Strollo, M. K., Guterman, S., Rogers, W. H., Li, A., Rodday, A. M. C., and Safran, D. G. Medicare prescription drug benefit progress report: findings from a 2006 national survey of seniors. Health Affairs 26, 5 (2007), w630\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009cw643.",
        "Newhouse, J. P. Medical care costs: how much welfare loss? The Journal of Economic Perspectives 6, 3 (1992), 3\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c21.",
        "Phelps, C. E., and Newhouse, J. P. Coinsurance, the price of time, and the demand for medical services. the Review of Economics and Statistics 56, 3 (1974), 334\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c342.",
        "Philipson, T., Berndt, E. R., Gottschalk, A. H., and Sun, E. Cost-benefit analysis of the fda: The case of the prescription drug user fee acts. Journal of Public Economics 92, 5 (2008), 1306\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1325.",
        "Proctor, B. D. Income, poverty, and health insurance coverage in the united states: 2010. Current Population Reports. US Census Bureau (2006).",
        "Sommers, B. D., Tomasi, M. R., Swartz, K., and Epstein, A. M. Reasons for the wide variation in medicaid participation rates among states hold lessons for coverage expansion in 2014. Health Affairs 31, 5 (2012), 909\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c919.",
        "Varian, H. R. Intermediate Microeconomics: A Modern Approach. WW Norton, 1993.",
        "Wallen, J., Roddy, P., and Meyers, S. M. Male-female differences in mental health visits under cost-sharing. Health services research 21, 2 Pt 2 (1986), 341.",
        "Weisbrod, B. The health care quadrilemma: an essay on technological change, insurance, quality of care, and cost containment. Journal of economic literature 29, 2 (1991), 523\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c552.",
        "Werblow, A., Felder, S., and Zweifel, P. Population ageing and health care expenditure: a school of red herrings? Health economics 16, 10 (2007), 1109\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1126.",
        "Yin, W., Basu, A., Zhang, J. X., Rabbani, A., Meltzer, D. O., and Alexander, G. C. The effect of the medicare part d prescription benefit on drug utilization and expenditures. Annals of Internal Medicine 148, 3 (2008), 169\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c177.",
        "Zweifel, P., Felder, S., and Meiers, M. Ageing of population and health care expenditure: a red herring? Health economics 8, 6 (1999), 485\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c496."
    ]
}